Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) have earned an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company.

Several equities analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, July 21st. Pareto Securities downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Monday, June 29th. Finally, Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd.

Swedish Orphan Biovitrum Stock Performance

BIOVF opened at $48.13 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.55 and a current ratio of 0.88. Swedish Orphan Biovitrum has a 52-week low of $29.18 and a 52-week high of $49.03. The firm has a market cap of $17.13 billion, a P/E ratio of 106.95 and a beta of 0.33. The business’s fifty day moving average is $48.38 and its 200-day moving average is $45.39.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Swedish biopharmaceutical company focused on developing, manufacturing and commercializing therapies for rare diseases. Its principal areas of activity include hematology, immunology and specialty care, with an emphasis on conditions that have limited treatment options and relatively small patient populations.

Sobi’s portfolio includes treatments for hemophilia and other bleeding disorders, such as Elocta, Alprolix and Vonvendi, as well as medicines for immune-mediated and hematologic conditions.